Data Builds on Roche's Dominance in Primary Progressive MS

Why It Matters

An effective oral therapy could broaden treatment options for PPMS patients and challenge Ocrevus' market dominance, reshaping the MS therapeutic landscape.

Key Takeaways

• Fenebrutinib met non‑inferiority vs Ocrevus in PPMS
• Oral BTK inhibitor reduced disability progression risk by 12%
• 9‑hole peg test improved 26% versus Ocrevus
• Roche plans regulatory filing for fenebrutinib soon
• Competitors' BTK candidates have failed late‑stage trials

Pulse Analysis

Primary progressive multiple sclerosis remains one of the most challenging neurological disorders, with only Ocrevus approved and generating nearly $8 billion in sales last year. The disease’s relentless disability trajectory and the need for intravenous infusions have left patients and clinicians yearning for more convenient, brain‑penetrant options. Oral BTK inhibitors, designed to target the underlying progressive biology directly within the central nervous system, promise to fill this therapeutic gap, offering a potential shift from infusion‑based care to daily oral regimens.

In the FENtrepid phase 3 trial, Roche’s fenebrutinib demonstrated non‑inferiority to Ocrevus on the composite confirmed disability progression endpoint (cCDP12) after 24 weeks. Although the overall risk reduction of 12% fell short of statistical significance, the drug showed a pronounced benefit in upper‑limb function, with a 26% improvement on the nine‑hole peg test and a 22% gain on a combined EDSS‑9HPT metric. These functional gains are clinically meaningful, as they translate to better daily independence for patients. The trial’s success paves the way for imminent regulatory filings, and Roche is also leveraging data from its FENhance 1 and 2 studies to explore indications in relapsing‑remitting MS.

Roche’s advancement comes at a time when rival BTK programs have stumbled—Sanofi’s tolebrutinib failed in PPMS, Merck’s evobrutinib was abandoned, and other candidates remain in late‑stage testing. By potentially delivering the first oral, high‑efficacy PPMS therapy in over a decade, fenebrutinib could erode Ocrevus’ market share and set a new standard for disease‑modifying treatments. The move also underscores a broader industry trend toward brain‑penetrant small molecules, signaling intensified competition and accelerated innovation in the multiple sclerosis arena.